Assembly Biosciences Stock News

PI, INST and ASMB made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 4, 2022.

Assembly Biosciences (ASMB) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

ARI, CB, PI, ASMB and URI have been added to the Zacks Rank #1 (Strong Buy) List on August 4, 2022.

ARI, CB, PI, ASMB and URI have been added to the Zacks Rank #1 (Strong Buy) List on August 4, 2022.

- Discontinues clinical development of vebicorvir, Assembly Bio’s first-generation core inhibitor, based on interim efficacy data from ongoing combination clinical studies

SOUTH SAN FRANCISCO, Calif., June 22, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative, investigational therapeutics

Some stocks currently trading in penny stock territory have unique advantages that makes it worthwhile to overlook the inherent risk involved in investing in these stocks. The post 7 Penny Stocks That

SOUTH SAN FRANCISCO, Calif., June 21, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative, investigational therapeutics t

SOUTH SAN FRANCISCO, Calif., June 21, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative, investigational therapeutics tar

SOUTH SAN FRANCISCO, Calif., June 03, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative, investigational therapeutics t

SOUTH SAN FRANCISCO, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative, investigational therapeutics ta

SOUTH SAN FRANCISCO, Calif., April 01, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatit

Assembly Biosciences press release (NASDAQ:ASMB): FY GAAP EPS of -$3.00 misses by $0.90.Revenue of $6.25M (-92.1% Y/Y) beats by $0.09M.

SOUTH SAN FRANCISCO, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and other viral diseases, today reported financial results and recent highlights for the fourth quarter and year ended December 31, 2021.

SOUTH SAN FRANCISCO, Calif., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and other viral diseases, today announced that John McHutchison, AO, MD, chief executive officer and president, will participate in a virtual fireside chat during the SVB Leerink 11 th Annual Global Healthcare Conference on Thursday, February 17, 2022 at 3:40 p.m. ET.